{"title":"Favipiravir:一种有效的Rna聚合酶调节抗流感药物","authors":"Shertate Yash, Kamble Sarika, Borse Laxmikant","doi":"10.13005/bbra/3102","DOIUrl":null,"url":null,"abstract":"ABSTRACT: Combination of all the aspects are covered in this review from anti-influenza drug.Several articles neglected to include a point of view. The majority of review papers emphasiseon epidemiology. In order to lessen the financial burden of disease and its negative effects, it is important to raise awareness about disease and how to manage it.The medicine favipiravir,additionally called T-705 (5-fluro-2-oxo-1H-pyrazine-3-carboxamide), by selection and powerfully inhibits the polymer-dependent polymer accelerator (RdRp) of polymer viruses. Favipiravir was discovred by the company Toyama Chemical Co., Ltd.By searching a chemical library for the respiratory illness virus's antiviral properties. Favipiravir-RTP (favipiravir ribofuranosyl-5′-triphosphate), the active version of the drug, is recognised by RdRpas a substrate and restrains the polymer accelerator's activityFavipiravir is efficient against a broad kind of subtypes and variations of respiratory disorder viruses.","PeriodicalId":9032,"journal":{"name":"Biosciences, Biotechnology Research Asia","volume":"7 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Favipiravir: An Effective Rna Polymerase Modulating Anti-Influenza Drug\",\"authors\":\"Shertate Yash, Kamble Sarika, Borse Laxmikant\",\"doi\":\"10.13005/bbra/3102\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"ABSTRACT: Combination of all the aspects are covered in this review from anti-influenza drug.Several articles neglected to include a point of view. The majority of review papers emphasiseon epidemiology. In order to lessen the financial burden of disease and its negative effects, it is important to raise awareness about disease and how to manage it.The medicine favipiravir,additionally called T-705 (5-fluro-2-oxo-1H-pyrazine-3-carboxamide), by selection and powerfully inhibits the polymer-dependent polymer accelerator (RdRp) of polymer viruses. Favipiravir was discovred by the company Toyama Chemical Co., Ltd.By searching a chemical library for the respiratory illness virus's antiviral properties. Favipiravir-RTP (favipiravir ribofuranosyl-5′-triphosphate), the active version of the drug, is recognised by RdRpas a substrate and restrains the polymer accelerator's activityFavipiravir is efficient against a broad kind of subtypes and variations of respiratory disorder viruses.\",\"PeriodicalId\":9032,\"journal\":{\"name\":\"Biosciences, Biotechnology Research Asia\",\"volume\":\"7 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-06-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biosciences, Biotechnology Research Asia\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.13005/bbra/3102\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biosciences, Biotechnology Research Asia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.13005/bbra/3102","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
摘要:本文从抗流感药物这一角度，结合各方面进行综述。有几篇文章忽略了一个观点。大多数综述论文强调流行病学。为了减轻疾病的经济负担及其负面影响，提高对疾病和如何管理疾病的认识非常重要。药物favipiravir，也被称为T-705(5-氟-2-氧-1 - h -吡嗪-3-carboxamide)，通过选择并有效抑制聚合物病毒的聚合物依赖性聚合物促进剂(RdRp)。Favipiravir是富山化学有限公司(Toyama Chemical Co.， ltd)在一个化学文库中搜索这种呼吸道疾病病毒的抗病毒特性时发现的。favipirvir - rtp (favipirvir核糖呋喃基-5 ' -三磷酸)是该药物的活性版本，被rdrpa识别为底物并抑制聚合物促进剂的活性。favipirvir对多种亚型和呼吸系统疾病病毒变体有效。
Favipiravir: An Effective Rna Polymerase Modulating Anti-Influenza Drug
ABSTRACT: Combination of all the aspects are covered in this review from anti-influenza drug.Several articles neglected to include a point of view. The majority of review papers emphasiseon epidemiology. In order to lessen the financial burden of disease and its negative effects, it is important to raise awareness about disease and how to manage it.The medicine favipiravir,additionally called T-705 (5-fluro-2-oxo-1H-pyrazine-3-carboxamide), by selection and powerfully inhibits the polymer-dependent polymer accelerator (RdRp) of polymer viruses. Favipiravir was discovred by the company Toyama Chemical Co., Ltd.By searching a chemical library for the respiratory illness virus's antiviral properties. Favipiravir-RTP (favipiravir ribofuranosyl-5′-triphosphate), the active version of the drug, is recognised by RdRpas a substrate and restrains the polymer accelerator's activityFavipiravir is efficient against a broad kind of subtypes and variations of respiratory disorder viruses.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
